From: Etiologies of conjugated hyperbilirubinemia in infancy: a systematic review of 1692 subjects
Extrahepatic BA | Ideopathic Neonatal Hepatitis | TPN associated cholestasis | Alagille Syndrome | Interlobular bile duct paucity | Alpha 1 Antitrypsin deficiency | Cystic Fibrosis | Infection | Hypopituitarism hypothyroid | Progressive familial intrahepatic cholestasis | Perinatal hypoxia-ischemia | Inspissated bile syndrome | Choledochal cyst | Hemolysis | Metabolic disease | Other a | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N/% | N/% | N/% | N/% | N/% | N/% | N/% | N/% | N/% | N/% | N/% | N/% | N/% | N/% | N/% | N/% | |
Hitch et. al [18] | 9 | 7 | 6 | - | 1 | 1 | - | - | - | - | - | - | 1 | 3 | ||
32.14% | 25.00% | 21.43% | 3.57% | 3.57% | 3.57% | 10.71% | ||||||||||
Tolia et. al [11] | 6 | 2 | 6 | - | 2 | 1 | - | 2 | - | - | - | - | - | - | - | 1 |
30.00% | 10.00% | 30.00% | 10.00% | 5.00% | 10.00% | 5.00% | ||||||||||
Tiker et. al [12] | 1 | 2 | 3 | - | - | - | - | 16 | 1 | - | 7 | - | - | 5 | 1 | 6 |
2.38% | 4.76% | 7.14% | 38.10% | 2.38% | 16.67% | 11.90% | 2.38% | 14.29% | ||||||||
Humphrey et. al [17] | 30 | 22 | - | 4 | 2 | 4 | 3 | 2 | 2 | 2 | - | 1 | 1 | - | - | 17 |
33.33% | 24.44% | 4.44% | 2.22% | 4.44% | 3.33% | 2.22% | 2.22% | 2.22% | 1.11% | 1.11% | 18.89% | |||||
Bazlul Karim et. al [5] | 16 | 15 | - | - | 1 | 1 | - | 22 | 3 | - | - | - | 4 | - | - | - |
25.81% | 24.19% | 1.61% | 1.61% | 35.48% | 4.84% | 6.45% | ||||||||||
Jiang et. al [10] | 23 | 22 | - | - | - | - | - | - | - | 1 | - | - | 2 | - | 2 | - |
46.00% | 44.00% | 2.00% | 4.00% | 4.00% | ||||||||||||
Fischler et. al [9] | 30 | 15 | - | 3 | - | 11 | 1 | 7 | 1 | 11 | - | - | - | - | - | 6 |
35.29% | 17.65% | 3.53% | 12.94% | 1.18% | 8.24% | 1.18% | 12.94% | 7.06% | ||||||||
Spivak et. al [13] | 7 | 6 | 5 | - | 6 | - | - | 1 | - | - | - | 3 | - | - | - | 5 |
21.21% | 18.18% | 15.15% | 18.18% | 3.03% | 9.09% | 15.15% | ||||||||||
Motala et. al [14] | 41 | 52 | Excludeds♦ | - | - | 6 | 1 | 35 | - | - | - | - | 5 | - | 5 | - |
28.28% | 35.86% | 4.14% | 0.69% | 24.14% | 3.45% | 3.45% | ||||||||||
Ipek et. al [16] | 4 | 7 | 8 | - | 2 | - | - | 9 | 4 | - | 28 | 6 | - | 15 | 6 | 3 |
4.35% | 7.61% | 8.70% | 2.17% | 9.78% | 4.35% | 30.43% | 6.52% | 16.30% | 6.52% | 3.26% | ||||||
Rafeey et. al [2] | 30 | 44 | - | 1 | 13 | - | 1 | 4 | - | 1 | - | - | 2 | - | 25 | 1 |
24.59% | 36.07% | 0.82% | 10.66% | 0.82% | 3.28% | 0.82% | 1.64% | 20.49% | 0.82% | |||||||
Johnson et. al [15] | 31 | 33 | - | - | - | 1 | - | 12 | - | - | - | 3 | 2 | - | - | 19 |
30.69% | 32.67% | 0.99% | 11.88% | 2.97% | 1.98% | 18.81% | ||||||||||
Stormon et. al [7] | 34 | 18 | 35 | 6 | 1 | 13 | 7 | 23 | 10 | 2 | 21 | 9 | 3 | - | 17 | 6 |
16.59% | 8.78% | 17.07% | 2.93% | 0.49% | 6.34% | 3.41% | 11.22% | 4.88% | 0.98% | 10.24% | 4.39% | 1.46% | 8.29% | 2.93% | ||
Mowat et. al [6] | 32 | 61 | - | - | 1 | 24 | 2 | 9 | - | - | - | - | 2 | - | 2 | 4 |
23.36% | 44.53% | 0.73% | 17.52% | 1.46% | 6.57% | 1.46% | 1.46% | 2.92% | ||||||||
Yachha et. al [4] | 33 | 7 | - | - | 2 | - | - | 5 | - | - | - | - | - | - | 2 | 11 |
55.00% | 11.67% | 3.33% | 8.33% | 3.33% | 18.33% | |||||||||||
Aanpreung et. al [3] | 56 | 58 | 46 | 2 | - | - | - | 25 | 12 | - | 6 | 1 | 14 | 4 | 8 | 17 |
22.49% | 23.29% | 18.47% | 0.80% | 10.04% | 4.82% | 2.41% | 0.40% | 5.62% | 1.61% | 3.21% | 6.83% | |||||
Danks et. al [19] | 55 | 69 | - | - | 11 | 8 | - | 22 | - | - | - | - | Excluded✧ | - | 6 | - |
32.16% | 40.35% | 6.43% | 4.68% | 12.87% | 3.51% |